Daniel Faga - 06 Jan 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
CEO, Director
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol
ANAB
Transactions as of
06 Jan 2024
Transactions value $
-$149,747
Form type
4
Filing time
09 Jan 2024, 19:05:32 UTC
Previous filing
05 Jan 2024
Next filing
26 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $0 +17.9K +2.01% $0.00 905K 06 Jan 2024 Direct F1, F2
transaction ANAB Common Stock Sale -$150K -6.87K -0.76% $21.81 898K 08 Jan 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Restricted Stock Unit Options Exercise $0 -17.9K -25% $0.00 53.6K 06 Jan 2024 Common Stock 17.9K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
F3 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4 The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.